NASDAQ: ESTAEstablishment Labs Holdings Inc Stock
$45.79-1.49 (-3.15%)
Updated Jan 10, 2025
ESTA Price
$45.79
Fair Value Price
N/A
Market Cap
$1.28B
52 Week Low
$32.00
52 Week High
$60.12
P/E
-17.75x
P/B
39.19x
P/S
7.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$153.07M
Earnings
-$70.61M
Gross Margin
65.1%
Operating Margin
-34.31%
Profit Margin
-46.1%
Debt to Equity
7.64
Operating Cash Flow
-$46M
Beta
1.3
Next Earnings
Feb 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ESTA Overview
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ESTA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
C
Momentum
C
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ESTA news, forecast changes, insider trades & much more!
ESTA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ESTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ESTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ESTA is poor value based on its book value relative to its share price (39.19x), compared to the US Medical Devices industry average (4.01x)
P/B vs Industry Valuation
ESTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ESTA due diligence checks available for Premium users.
Valuation
ESTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.75x
Industry
37.15x
Market
30.06x
ESTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
39.19x
Industry
4.01x
ESTA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ESTA's financial health
Profit margin
Revenue
$40.2M
Net Income
-$16.7M
Profit Margin
-41.5%
ESTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ESTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$282.7M
Liabilities
$250.0M
Debt to equity
7.64
ESTA's short-term assets ($182.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESTA's long-term liabilities ($199.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ESTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.5M
Investing
-$2.8M
Financing
-$28.0k
ESTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ESTA vs Medical Device Stocks
Establishment Labs Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.